Clinical trials: Schizophrenia Disorder
Schizophrenia
Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia
The purpose of this study is to compare the efficacy and tolerability of aripiprazole to olanzapine over 26 weeks for the treatment of schizophrenia
- Trial name
- NCT00712686
- Testing
- Aripiprazole, Olanzapine
- Volunteers
- 690 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Safety and Efficacy of Seroquel in First Episode Schizophrenia
To compare the safety, tolerability and efficacy of Seroquel and risperidone in first episode schizophrenia
- Trial name
- NCT00254241
- Testing
- Seroquel and Risperidone
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Schizophrenia, Impaired Cognition
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
- Trial name
- NCT01714661
- Testing
- EVP-6124
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 753 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia
The purpose of this study is to evaluate efficacy, safety and tolerability of flexible, once-daily doses of paliperidone extended-release (ER) in patients with schizophrenia from Argentina and Colombia that previously failed…
- Trial name
- PERFLEX (NCT01724359)
- Testing
- Paliperidone ER
- Where
- 5 sites in Argentina, Colombia
- Volunteers
- 95 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia
The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients
It's a prospective, non-interventional, observational Post-marketing Surveillance..
- Trial name
- NCT04432688
- Testing
- Lurasidone HCl
- Where
- 7 sites in China
- Volunteers
- 3,192 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Schizophrenia, Alzheimer's Disease Psychosis
A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects
This is a single-center, randomized, double-blind, placebo-controlled, ascending single oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects.
- Trial name
- NCT06556966
- Testing
- LY03020
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
eMotiph: E-mental Health Solution for Patients With Schizophrenia
Although the main objective of current schizophrenia intervention programs is the reduction of symptoms, its rates are around 36%, and recovery rates are 16.5%.
- Trial name
- NCT05345977
- Testing
- eMotiph
- Where
- Spain
- Volunteers
- 7 people
- Sponsor
- Grupo Pulso
Cognitive Impairment, Schizophrenia
Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia
The purpose of this study is to assess the safety and effects on electrical activity in the brain of an investigational drug (RL-007) for improving cognition in patients with schizophrenia
- Trial name
- NCT04822883
- Testing
- RL-007
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Recognify Life Sciences
Bipolar I Disorder, Bipolar II Disorder
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT07116694
- Testing
- BXCL501 Sublingual Film
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- BioXcel Therapeutics Inc
Schizophrenia
The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics
The purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.
- Trial name
- NCT00986531
- Testing
- AZD8529
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Schizophrenia
A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville
The purpose of this study is to establish bioequivalence of paliperidone ER tablets manufactured at Gurabo as compared to paliperidone ER tablets manufactured at Vacaville, administered as a single dose of 12 mg under fasted…
- Trial name
- NCT00790777
- Testing
- Paliperidone ER
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cognitive Impairment Associated With Schizophrenia
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)
The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery (MCCB).
- Trial name
- TALLY (NCT03745820)
- Testing
- BIIB104
- Where
- 60 sites in United States, Germany and 3 more
- Volunteers
- 195 people
- Sponsor
- Biogen
Schizophrenia
Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use
The purpose of the study is to determine whether there is an increased all-cause mortality in sertindole-treated patients in comparison to patients treated with a well-known antipsychotic (risperidone) when used under normal…
- Trial name
- SCoP (NCT00856583)
- Testing
- Sertindole, Risperidone
- Volunteers
- 9,809 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Schizoaffective Disorder
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.
- Trial name
- NCT04512066
- Testing
- RO6889450, Risperidone
- Where
- 40 sites in United States, Japan and 2 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.
- Trial name
- NCT02477670
- Testing
- AVP-786
- Where
- 17 sites in United States
- Volunteers
- 145 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese Subjects
This is a phase 1, randomized (a process that is used to decide whether you will take study drug or a placebo during the study), inpatient study which will assess the safety and tolerability of HTC-867 in healthy male Japanese…
- Trial name
- NCT01268124
- Testing
- HTC-867
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics
This is a randomized, double-blind, placebo-controlled, sequential cohort, ascending oral dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of EVP-6308 administered for 14 days in subjects with…
- Trial name
- NCT02037074
- Testing
- Drug: EVP-6308
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders
Study to learn if the alternate formulation is effective in agitated schizophrenic patients
- Trial name
- NCT00036127
- Testing
- aripiprazole
- Where
- 16 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia
This is an open-label, multiple dose, PK and safety study in patients with chronic, stable schizophrenia or schizoaffective disorder.
- Trial name
- NCT02411526
- Testing
- ZX003 (Risperidone-SABER®), Risperdal Consta, Oral Risperidone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Zogenix, Inc.
Schizophrenia
A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia
The primary objective of this protocol is to assess the efficacy of two dose strengths of varenicline (0.5 mg BID and 1mg BID) as adjunctive treatment for cognitive impairment in symptomatically stable outpatient schizophrenic…
- Trial name
- NCT00743847
- Testing
- varenicline
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.